Intracellular Pharmacology and Biochemistry of Methotrexate and 6-Mercaptopurine in Childhood Acute Lymphoblastic Leukemia

  • C. W. Keuzenkamp-Jansen
  • J. P. M. Bökkerink
  • J. M. F. Trijbels
  • M. A. H. v.d. Heijden
  • R. A. De Abreu
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 370)

Abstract

After treatment with methotrexate (MTX), 6-mercaptopurine (6MP) demonstrated a synergistic effect and an enhanced incorporation into DNA and RNA in human lymphoblastic cell lines1.

Keywords

Toxicity Leukemia Oncol Methotrexate Pyrimidine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    J.P.M. Bökkerink, M.A.H. Bakker, T.W. Hulscher, et al, Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages. Biochem. Pharmacol 37: 2321 (1988).PubMedCrossRefGoogle Scholar
  2. 2.
    C.W. Keuzenkamp-Jansen, J.P.M. Bökkerink, R.A. De Abreu, et al, Pharmacokinetics of 24 hours intravenous high-dose 6-mercaptopurine after 24 hours intravenous methotrexate in childhood acte lymphoblastic leukemia. Med. Ped. Oncol., 21: 539 (1993).Google Scholar
  3. 3.
    J.P.M. Bökkerink, C.W. Keuzenkamp-Jansen, New use of an old drug: clinical application and pharmacokinetics of intravenous 6-mercaptopurine. In: R. Riccardi, J. Borsi (eds), The Role of Clinical Pharmacology in Pediatric Oncology. Rome: Tipolitografia Feroce, 105 (1992).Google Scholar
  4. 4.
    D.M. Tidd, A.R.P. Paterson, A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res. 34: 738 (1974).PubMedGoogle Scholar
  5. 5.
    M.H.J. Vogt, E.H. Stet, R.A. De Abreu, et al, The importance of methylthio-IMP for methylmercaptopurine ribonucleoside cytotoxicity in Molt F4 human malignant T-lymphoblasts, Biochem. Biophys. Acta 1181: 189 (1993).PubMedCrossRefGoogle Scholar
  6. 6.
    R.A. De Abreu, G.J. Peters, J.A.J.M. Bakkeren, et al, Discrepancies in ribonucleotide concentrations in human lymphocytes isolated from heparinized and defibrinized blood. Clin. Chim. Acta 145: 349 (1985)PubMedCrossRefGoogle Scholar
  7. 7.
    E.H. Stet, R.A. De Abreu, Y.P.G. Janssen, et al, A Biochemical basis for synergism of 6-mercaptopurine and mycophenolic acid in Molt F4 human malignant T-lymphoblastic cell line, Biochim. Biophys. Acta 1180: 277 (1993).PubMedCrossRefGoogle Scholar
  8. 8.
    D. de Korte, W.A. Haverkort, A.H. van Gennip, et al, Nucleotide profiles of normal human blood cells determined by high-performance liquid chromatography. Analyt. Biochem. 147: 197 (1985).PubMedCrossRefGoogle Scholar
  9. 9.
    L. Lennard, J.S. Lilleyman, Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. Leukemia, J. Clin. Oncol. 7: 1816 (1989).Google Scholar
  10. 10.
    W.E. Evans, M. Horner, Y. Qin Chu, et al, Altered mercaptopurine metabolism, toxic effects and dosage requirement in a TPMT deficient child with acute lymphoblastic leukemia, J. Pediatr. 119: 985 (1991).PubMedCrossRefGoogle Scholar
  11. 11.
    L. Lennard, J.A. Van Loon, J.S. Lilleyman, et al, Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte TPMT activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol. Ther. 41: 18 (1987).PubMedCrossRefGoogle Scholar
  12. 12.
    N. Erb, I. Ekem, D. Harms, et al, Differing metabolism of 6-thioguanine versus 6-mercaptopurine in maintenance treatment of childhood acute lymphoblastic leukemia. Ann. Hematol. 68(suppl 1) A93 (1994).Google Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • C. W. Keuzenkamp-Jansen
    • 1
  • J. P. M. Bökkerink
    • 1
  • J. M. F. Trijbels
    • 1
  • M. A. H. v.d. Heijden
    • 1
  • R. A. De Abreu
    • 1
  1. 1.Center for Pediatric OncologyUniversity HospitalNijmegenThe Netherlands

Personalised recommendations